2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Sales - EUR | 23.203 | 42.745 | 50.102 | 21.125 | 107.134 | 150.622 | 208.008 | 271.020 | 369.798 | 447.706 |
Total Income - EUR | 23.203 | 42.745 | 50.103 | 22.009 | 128.059 | 176.820 | 236.474 | 291.683 | 391.541 | 471.869 |
Total Expenses - EUR | 4.526 | 5.800 | 13.645 | 13.007 | 45.980 | 122.195 | 136.675 | 175.173 | 165.711 | 288.038 |
Gross Profit/Loss - EUR | 18.677 | 36.945 | 36.459 | 9.003 | 82.079 | 54.624 | 99.799 | 116.509 | 225.830 | 183.831 |
Net Profit/Loss - EUR | 17.981 | 35.663 | 35.456 | 8.791 | 81.007 | 53.118 | 97.866 | 114.420 | 222.196 | 179.996 |
Employees | 1 | 1 | 1 | 1 | 1 | 5 | 10 | 14 | 12 | 16 |
Check the financial reports for the company - Oximed-Hbot Srl
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Fixed Assets | 8.090 | 6.934 | 5.652 | 62.940 | 226.993 | 229.887 | 211.924 | 192.955 | 161.025 | 436.206 |
Current Assets | 16.892 | 54.871 | 55.992 | 216.292 | 51.505 | 70.313 | 163.684 | 251.582 | 267.450 | 69.209 |
Inventories | 0 | 0 | 0 | 0 | 1.232 | 745 | 0 | 0 | 0 | 370 |
Receivables | 10.932 | 27.897 | 52.107 | 203.448 | 30.969 | 30.821 | 76.015 | 71.848 | 72.584 | 34.409 |
Cash | 5.960 | 26.975 | 3.886 | 12.843 | 19.305 | 38.746 | 87.669 | 179.735 | 194.866 | 34.431 |
Shareholders Funds | 24.662 | 60.530 | 60.075 | 8.844 | 89.689 | 141.070 | 236.262 | 345.442 | 222.245 | 401.566 |
Social Capital | 45 | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 |
Debts | 320 | 1.275 | 1.569 | 72.538 | 15.500 | 10.698 | 14.789 | 13.083 | 125.438 | 44.085 |
Income in Advance | 0 | 0 | 0 | 197.849 | 173.309 | 148.475 | 124.589 | 101.200 | 80.847 | 59.997 |
Exchange rate - RON | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 | 4.4821 |
Main CAEN | "8622 - 8622" | |||||||||
CAEN Financial Year |
8622
|
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Comments - Oximed-Hbot Srl